Yasmin Halwani1, Liliana D Kojic2, Simon K Chan3, Terry P Phang1, Hamid Masoudi4, Steven J M Jones3, Ivan R Nabi2, Sam M Wiseman5. 1. Department of Surgery, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada. 2. Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, British Columbia, Canada. 3. Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada. 4. Department of Pathology and Laboratory Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada. 5. Department of Surgery, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: smwiseman@providencehealth.bc.ca.
Abstract
BACKGROUND: Autocrine motility factor receptor (AMFR) has been linked to metastasis and tumorigenicity. The aim of this study was to evaluate expression and prognostic significance of AMFR in colorectal carcinoma. METHODS: AMFR expression was evaluated in 127 colon cancer specimens, 131 rectal cancer specimens, and 47 colonic and 25 rectal corresponding lymph node metastases. Clinicopathological correlates of prognostic significance were established by univariate and multivariate analysis. Spearman's correlation determined the association of expression between cancers and their metastases. RESULTS: AMFR was over-expressed by 22% of colon cancers and 18% of rectal cancers. AMFR over-expression correlated significantly with improved disease-free survival (DFS) (P < .05) in colon cancer and decreased DFS in corresponding nodal metastases. In rectal cancer, AMFR over-expression significantly correlated with decreased overall survival, DFS, and disease-specific survival (P < .001, P = .031, P = .005, respectively) and decreased overall survival in corresponding metastases. CONCLUSION: AMFR may serve as a molecular prognosticator for colon cancer and rectal cancer.
BACKGROUND:Autocrine motility factor receptor (AMFR) has been linked to metastasis and tumorigenicity. The aim of this study was to evaluate expression and prognostic significance of AMFR in colorectal carcinoma. METHODS:AMFR expression was evaluated in 127 colon cancer specimens, 131 rectal cancer specimens, and 47 colonic and 25 rectal corresponding lymph node metastases. Clinicopathological correlates of prognostic significance were established by univariate and multivariate analysis. Spearman's correlation determined the association of expression between cancers and their metastases. RESULTS:AMFR was over-expressed by 22% of colon cancers and 18% of rectal cancers. AMFR over-expression correlated significantly with improved disease-free survival (DFS) (P < .05) in colon cancer and decreased DFS in corresponding nodal metastases. In rectal cancer, AMFR over-expression significantly correlated with decreased overall survival, DFS, and disease-specific survival (P < .001, P = .031, P = .005, respectively) and decreased overall survival in corresponding metastases. CONCLUSION:AMFR may serve as a molecular prognosticator for colon cancer and rectal cancer.